Stockscreener 앱 받기
1.50
2.04%
0.03
전일 마감가:
$1.47
열려 있는:
$1.43
하루 거래량:
500.12K
Relative Volume:
0.70
시가총액:
$166.54M
수익:
$21.05M
순이익/손실:
$-142.93M
주가수익비율:
-1.0795
EPS:
-1.3895
순현금흐름:
$-184.07M
1주 성능:
-6.83%
1개월 성능:
-3.85%
6개월 성능:
-18.48%
1년 성능:
-10.18%
1일 변동 폭
$1.42
$1.5189
1주일 범위
$1.37
$1.61
52주 변동 폭
$1.09
$3.3999
알렉터 Stock (ALEC) Company Profile
명칭
Alector Inc
전화
415-231-5660
주소
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.50 | 163.21M | 21.05M | -142.93M | -184.07M | -1.3895 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
알렉터 Stock (ALEC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2026-03-10 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-10-22 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-22 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-10-22 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-10-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-07-28 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-17 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-11-29 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-26 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-14 | 업그레이드 | Stifel | Hold → Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-09-25 | 개시 | Goldman | Sell |
| 2023-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-13 | 개시 | Goldman | Sell |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-27 | 개시 | William Blair | Outperform |
| 2021-01-15 | 재개 | BofA Securities | Buy |
| 2020-06-24 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Goldman | Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-19 | 개시 | Stifel | Buy |
| 2019-11-21 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | Barclays | Overweight |
| 2019-03-04 | 개시 | BofA/Merrill | Buy |
| 2019-03-04 | 개시 | Morgan Stanley | Overweight |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
모두보기
알렉터 주식(ALEC)의 최신 뉴스
Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary - Quartr
Alector (ALEC) Proxy filing Summary - Quartr
Alector Q1 2026 Earnings: Narrower Loss Surprises, Yet Shares Dip Amid Revenue AbsenceCapex Guidance - DonanımHaber
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - Sahm
GSK exits Alector neurodegeneration alliance after trial failures - The Pharma Letter
Form 4 Alector Inc For: 9 July By Investing.com - Investing.com Nigeria
Alector (ALEC) awards 20,000 RSUs to principal accounting officer - Stock Titan
GSK ends brain drug alliance with Alector - BioPharma Dive
GSK Bids Farewell To Alector Dementia Deal - insights.citeline.com
GSK Walks Away From AlectorPipeline Reset Story Begins (NASDAQ:ALEC) - Seeking Alpha
GSK Terminates Neuroscience Collaboration with Alector Following Drug Trial SetbacksEPS Surprise History - dars.gov.et
Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE) - Seeking Alpha
Alector (ALEC) Shares Drop 13% Following Termination of GSK Coll - GuruFocus
Alector and GSK partnership to end after dementia, Alzheimer’s drug failures - whbl.com
Alector, Inc. Terminates Material Definitive Agreement – Key 8-K Filing Update July 2026 - Minichart
Alector and GSK partnership to end after dementia, Alzheimer's drug failures - Reuters
Alector Ends GSK Collaboration, Retires Hercules Capital Debt - TipRanks
Alector to End GSK Progranulin Collaboration; Repays $10.4 Million Hercules Loan - TradingView
Alector (ALEC) sees GSK end antibody collaboration while repaying $10.4M loan - Stock Titan
According to a filing submitted to the U.S. Securities and Exchange Commission (SEC), GlaxoSmithKline has decided to terminate its collaboration and licensing agreement with Alector Inc., with the termination to take effect on January 2, 2027. - Bitget
ALEC Q1 2026 Earnings: Narrowing Losses with 39.95% EPS Beat; Stock Rises 2.49%Investor Earnings Call - dars.gov.et
Alector Inc. (ALEC) Recovers From Support as Shares Edge HigherValue Area Low - DonanımHaber
ALEC Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive SentimentCEO Earnings Statement - dars.gov.et
0Z2 Forecast — Price Target — Prediction for 2027 - TradingView
Alector, Inc. Actuals & Estimates (NASDAQ:ALEC) - TradingView
ALEC Forecast — Price Target — Prediction for 2027 - TradingView
Alector (ALEC) Surges 11.45% as Shares Test Key Resistance at $2.1Buy Signal Reports - dars.gov.et
A2PCBM Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Alector, Inc. – GETTEX:0Z2 - TradingView
Price to sales forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Enterprise value to revenue forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Price to sales forward of Alector, Inc. – GETTEX:0Z2 - TradingView
Price to book forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Enterprise value to EBITDA forward of Alector, Inc. – GETTEX:0Z2 - TradingView
Enterprise value to EBIT forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Alector Inc. (ALEC) Q1 2026 Earnings: EPS Beat on Narrower Loss, No Revenue YetEarnings Season Outlook - dars.gov.et
Alector Inc. (ALEC) Edges Higher as Stock Approaches Key ResistanceHead and Shoulders - dars.gov.et
ALEC Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Double-Digit RallyGeographic Revenue Trends - dars.gov.et
Alector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy Readthrough - Yahoo Finance
Alector Inc (ALEC) Institutional Confidence - TradingKey
Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alector Inc (ALEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alector Inc (ALEC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alector Inc (ALEC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alector Inc (ALEC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alector Inc (ALEC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alector Shareholders Back Directors, Auditor and Executive Pay - TipRanks
[8-K] Alector, Inc. Reports Material Event - Stock Titan
Alector (ALEC) director Kristine Yaffe granted 28,700 RSUs and options - Stock Titan
알렉터 (ALEC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알렉터 주식 (ALEC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wong-Sarad Grace | Principal Accounting Officer |
Jun 02 '26 |
Sale |
1.97 |
5,709 |
11,271 |
98,936 |
| Wong-Sarad Grace | Principal Accounting Officer |
Jun 03 '26 |
Sale |
1.88 |
3,475 |
6,543 |
95,461 |
| Berkley Neil Lindsay | CFO & Chief Business Officer |
Jun 02 '26 |
Sale |
1.97 |
19,360 |
38,221 |
379,900 |
0.80%
2.11%
자본화:
|
볼륨(24시간):